Bridget M. Kuehn

Low-grade gliomas may be classified into three distinct prognostic categories based on genomic data.

Continuing Avastin (bevacizumab) in patients with recurrent glioblastoma after progression of the disease does not improve patient outcomes, according to results from the phase 2 CABARET trial.

Adding the immunotherapeutic vaccine Rintega (rindopepimut) to Avastin (bevacizumab) may help boost survival in patients with a genetic subtype of glioblastoma associated with poor outcomes.